Floatz logo

Dasabuvir

Compensated Cirrhosis

AbbVieSmall moleculePhase 3Dormant
A
82/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
75/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Compensated Cirrhosis cohort.

Asset / SponsorPhaseRating
OMBITASVIR
AbbVie
Phase 3A
PARITAPREVIR
AbbVie
Phase 3A
RITONAVIR
AbbVie
Phase 3BBB
GLECAPREVIR
AbbVie
Phase 3BBB
Abt-530
AbbVie
Phase 3BBB

View all 16 →

Same molecule, other indications

Dasabuvir is also rated in:

chronic hepatitis C virus infectionDormant
A
Indicative ·
82 / 100
View asset →
hepatitis C virus infectionDormant
A
Indicative ·
82 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →